Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISS T-002: HIV-1 Tat Vaccine in HAART-treated Adults
NCT00751595Phase 2Completed
- Start
- Sep 2008
- Primary completion
- Jun 2012
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of HIV-1 Tat vaccine in human immunodeficiency virus infection (HIV) (4 arms). Primary endpoints: Humoral immune response to Tat at 144 weeks and Cellular immune response to Tat at 144 weeks. Started Sep 2008; status: completed.
02
Drugs
HIV-1 Tat vaccine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00751595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00751595.